Qiming Venture Partners Portfolio Companies Feature on QbitAI 2025H1 AI 100 Product Rankings
The 2025 H1 AI 100 flagship product list represents the leading players in the current landscape, while the innovative product list spotlights the seed contenders for future markets. Together, these two lists — spanning from comprehensive strength to breakthrough potential — sketch out a more multidimensional and authentic map of AI products, offering industry participants and observers a set of reference-worthy examples.
Recently, QbitAI Think Tank released the 2025H1 AI 100 dual product rankings. This selection comprises two lists — a flagship product ranking and an innovative product ranking. The former represents the leading cohort in the current landscape, while the latter spotlights future market contenders. Together, these two rankings map out a more multidimensional and realistic picture of AI products, offering reference points for industry participants and observers alike.
Portfolio companies of Qiming Venture Partners — Zhipu AI, StepFun, Zhihu (NYSE: ZH, 02390.HK), and Meitu (01357.HK) — were named to the 2025H1 AI 100 Flagship Products list. Zhipu AI, DeepWise, Shengshu Technology, and Mafengwo were named to the 2025H1 AI 100 Innovative Products list.
Zhipu AI
(Zhipu Qingyan, Zhipu AI Open Platform)
StepFun
(Step AI)
Zhihu
(Zhihu Zhida)
Meitu
(Meitu Design Studio, Meitu Xiuxiu)
Selected for
2025H1 AI 100 Flagship Products
Zhipu AI
(AutoGLM)
DeepWise
(Bohr Research Space Station)
Shengshu Technology
(Vidu)
Mafengwo
(Mafengwo AI Itinerary)
Selected for
2025H1 AI 100 Innovative Products
· QbitAI Think Tank 2025H1 AI 100 Dual Product Rankings
QbitAI Think Tank employed a dual evaluation system combining quantitative and qualitative metrics. On the quantitative side, real user data formed the foundation, covering four core dimensions — user scale, user growth, user activity, and user stickiness — with over 20 specific indicators including total downloads, new downloads, active users, and retention rates. On the qualitative side, the focus was on long-term growth potential, with expert assessments and user research evaluating underlying technology, market opportunity, product design, monetization potential, team background, and growth velocity.
QbitAI Think Tank notes that these AI 100 dual rankings reveal a double-helix ecosystem: on one side, flagship products are deepening and integrating — they represent the most reliable and mature AI experiences available today, gradually evolving from "tools" into "assistants"; on the other side, innovative products are breaking into new markets and experimenting — they represent the birth of new demands, the validation of new approaches, and the embryonic forms of new business models.
Source | QbitAI Think Tank
Past Coverage
Qiming Headlines | 2025 WAIC "Qiming Venture Partners · Entrepreneurship and Investment Forum — Venture Capital Enters the AI Technology and Application Resonance Cycle" Successfully Held Qiming Perspectives | Technology Grows Upward, Applications Take Root Downward — AI Resonance Cycle and 2025 Top 10 AI Outlooks Released Qiming Stars | Multiple Qiming Venture Partners Portfolio Companies Named to QbitAI's 2025 Notable AIGC Companies and Products Rankings
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage outstanding companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, with more than 210 exiting through listings on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, among others.